Tue. 27 Feb 2024, 5:55am ET
Benzinga
Earnings, Earnings Beats, News
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.76) by 5.26 percent. The company reported quarterly sales of $13.53 million which beat the analyst consensus estimate of $11.34 million by 19.28 percent. This is a 356.81 percent increase over sales of $2.96 million the same period last year.